...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology >Clinical effect of hormonal replacement therapy with estradiol associated with noretisterone or drospirenone. A prospective randomized placebo controlled study
【24h】

Clinical effect of hormonal replacement therapy with estradiol associated with noretisterone or drospirenone. A prospective randomized placebo controlled study

机译：雌二醇与去甲睾酮或屈螺酮的激素替代治疗的临床效果。前瞻性随机安慰剂对照研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The study was performed to compare the clinical effect of a hormone replacement therapy (HRT) with two different progestins. Postmenopausal women (PMW) with climacteric symptoms (CS) randomly received for 12 months orally, either placebo (n = 20), 1 mg estradiol (E) plus 0.5 mg noretisterone acetate (NETA; n = 40), or 2 mg drospirenone (DRSP; n = 40), a testosterone- and spironolactone-derived molecule, respectively. Weight (W) declined only during E/DRSP (p < 0.04 versus placebo). Fat mass (FM) decreased, similarly, during E/NETA and E/DRSP. Intracellular water (ICW) did not change, while extracellular water (ECW) decreased during E/DRSP (p < 0.0001) (p < 0.002 versus E/NETA). During E/NETA and E/DRSP, similar decreases were observed for insulin resistance (IR) by the homeostatic model assessment for IR (HOMA-IR) (p < 0.0001 versus placebo for both), systolic (p < 0.04 versus placebo for both) and diastolic (p < 0.002) blood pressure (BP). Lipids did not change. In comparison to placebo CS, by the Kupperman Index (KI), significantly declined (p < 0.0001) during E/NETA or E/DRSP. Menopause-specific Quality of Life (MENQoL) significantly declined versus placebo (p < 0.04) during both E/NETA and E/DRSP. In conclusion, differences between the two progestins are mainly limited to body composition (BC), where the addition of DRSP decreases ECW and body W (BW).
机译：进行该研究以比较激素替代疗法（HRT）与两种不同孕激素的临床效果。绝经后症状（CSW）的绝经后妇女（PMW）口服接受为期12个月的安慰剂（n = 20），1 mg雌二醇（E）加0.5 mg乙酸去甲睾酮（NETA; n = 40）或2 mg屈螺酮（ DRSP; n = 40），分别是睾丸激素和螺内酯的分子。体重（W）仅在E / DRSP期间下降（相对于安慰剂，p <0.04）。同样，在E / NETA和E / DRSP期间，脂肪量（FM）下降。在E / DRSP期间，细胞内水（ICW）不变，而细胞外水（ECW）下降（p <0.0001）（相对于E / NETA，p <0.002）。在E / NETA和E / DRSP期间，通过IR（HOMA-IR）稳态模型评估（两者均相对于安慰剂，p <0.0001），收缩期（两者均相对于安慰剂，p <0.04），观察到胰岛素抵抗（IR）的相似降低。 ）和舒张压（p <0.002）血压（BP）。脂质没有改变。与安慰剂CS相比，通过Kupperman指数（KI），在E / NETA或E / DRSP期间显着下降（p <0.0001）。在E / NETA和E / DRSP期间，绝经期生活质量（MENQoL）与安慰剂相比均显着下降（p <0.04）。总之，两种孕激素之间的差异主要限于身体成分（BC），其中添加DRSP会降低ECW和身体W（BW）。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号